199 related articles for article (PubMed ID: 37526844)
1. Canadian Regulatory Framework and Regulatory Requirements for Cell and Gene Therapy Products.
Wang J; Griffiths E; Tounekti O; Nemec M; Deneault E; Lavoie JR; Ridgway A
Adv Exp Med Biol; 2023; 1430():91-116. PubMed ID: 37526844
[TBL] [Abstract][Full Text] [Related]
2. Regulatory Oversight of Cell and Gene Therapy Products in Canada.
Ridgway A; Agbanyo F; Wang J; Rosu-Myles M
Adv Exp Med Biol; 2015; 871():49-71. PubMed ID: 26374212
[TBL] [Abstract][Full Text] [Related]
3. The regulation of cell therapy products in Canada.
Ridgway AA
Biologicals; 2015 Sep; 43(5):406-9. PubMed ID: 26141550
[TBL] [Abstract][Full Text] [Related]
4. Workshop to address gaps in regulation of minimally manipulated autologous cell therapies for homologous use in Canada.
Chisholm J; von Tigerstrom B; Bedford P; Fradette J; Viswanathan S
Cytotherapy; 2017 Dec; 19(12):1400-1411. PubMed ID: 28964743
[TBL] [Abstract][Full Text] [Related]
5. Current state of Health Canada regulation for cellular and gene therapy products: potential cures on the horizon.
Chisholm J; Ruff C; Viswanathan S
Cytotherapy; 2019 Jul; 21(7):686-698. PubMed ID: 31196821
[TBL] [Abstract][Full Text] [Related]
6. Current practices and reform proposals for the regulation of advanced medicinal products in Canada.
Viswanathan S; Bubela T
Regen Med; 2015; 10(5):647-63. PubMed ID: 26237706
[TBL] [Abstract][Full Text] [Related]
7. Medical device regulation for manufacturers.
McAllister P; Jeswiet J
Proc Inst Mech Eng H; 2003; 217(6):459-67. PubMed ID: 14702983
[TBL] [Abstract][Full Text] [Related]
8. Regulatory Oversight of Cell and Gene Therapy Products in Malaysia.
Loh EYX; Ab Ghani A; Ahmad R
Adv Exp Med Biol; 2023; 1430():181-195. PubMed ID: 37526848
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Clinical Research for Cellular and Gene Therapy Products in India.
Dalal V; Lata H; Kharkwal G; Jotwani G
Adv Exp Med Biol; 2023; 1430():135-154. PubMed ID: 37526846
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for Regulating the Environmental Risk of Shedding for Gene Therapy and Oncolytic Viruses in Canada.
Bubela T; Boch R; Viswanathan S
Front Med (Lausanne); 2019; 6():58. PubMed ID: 30984761
[TBL] [Abstract][Full Text] [Related]
11. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
Lucas-Samuel S; Ferry N; Trouvin JH
Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
[TBL] [Abstract][Full Text] [Related]
12. Regulatory Oversight of Cell, Tissue, and Gene Therapy Products in Singapore.
Ong LL
Adv Exp Med Biol; 2023; 1430():197-210. PubMed ID: 37526849
[TBL] [Abstract][Full Text] [Related]
13. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
14. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 3: Porcine islet product manufacturing and release testing criteria.
Rayat GR; Gazda LS; Hawthorne WJ; Hering BJ; Hosking P; Matsumoto S; Rajotte RV
Xenotransplantation; 2016; 23(1):38-45. PubMed ID: 26923763
[TBL] [Abstract][Full Text] [Related]
15. The Regulation of Cell Therapy and Gene Therapy Products in Switzerland.
Bukovac PK; Hauser M; Lottaz D; Marti A; Schmitt I; Schochat T
Adv Exp Med Biol; 2023; 1430():41-58. PubMed ID: 37526841
[TBL] [Abstract][Full Text] [Related]
16. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Risk management frameworks for human health and environmental risks.
Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
[TBL] [Abstract][Full Text] [Related]
19. Progress and challenges in viral vector manufacturing.
van der Loo JC; Wright JF
Hum Mol Genet; 2016 Apr; 25(R1):R42-52. PubMed ID: 26519140
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
